中华心血管病杂志最新文献

{"title":"[Clinical challenges and research progress in variants of uncertain significance of inherited cardiovascular diseases].","authors":"J Tang, X Y Sun, Y Shen, K Hong","doi":"10.3760/cma.j.cn112148-20250624-00463","DOIUrl":"10.3760/cma.j.cn112148-20250624-00463","url":null,"abstract":"","PeriodicalId":38755,"journal":{"name":"中华心血管病杂志","volume":"54 3","pages":"349-353"},"PeriodicalIF":0.0,"publicationDate":"2026-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147500108","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Burden, trends and gender disparities of alcoholic cardiomyopathy in China from 1990 to 2021].","authors":"Z Fang, X F Luo, Y H Zhang, J Zhang","doi":"10.3760/cma.j.cn112148-20250513-00348","DOIUrl":"10.3760/cma.j.cn112148-20250513-00348","url":null,"abstract":"<p><p><b>Objectives:</b> To analyze the burden level, temporal trends, and gender and age disparities of alcoholic cardiomyopathy (ACM) in China from 1990 to 2021. <b>Methods:</b> Data were extracted from the Global Burden of Disease 2021 study database. Core metrics for ACM in China-including prevalent cases, deaths, and disability-adjusted life years (DALYs)-were extracted. The absolute numbers, rates (per 100 000 population), and variation characteristics of the above mentioned disease burden parameters were analyzed by stratification according to age and gender. The Joinpoint regression model was employed to calculate the estimated annual percentage change and average annual percentage change for analyzing the segmented trends of disease burden. Decomposition analyses were conducted to attribute the changes in disease burden to three independent factors: population growth, population aging, and changes in epidemiological rates, so as to quantify the absolute contribution value and relative contribution ratio of each factor to the changes in disease burden. <b>Results:</b> In 2021, the number of prevalent cases of ACM in China was 28 103 (95% uncertainty interval (<i>UI</i>) 22 175-34 991), the number of deaths was 1 861 (95%<i>UI</i> 318-2 987), and the DALYs reached 64 746 person-years (95%<i>UI</i> 12 595-102 876 person-years). The corresponding rates were 1.98 (95%<i>UI</i> 1.56-2.46), 0.13 (95%<i>UI</i> 0.02-0.21), and 4.55 (95%<i>UI</i> 0.89-7.23) per 100 000 population, respectively. The prevalence of ACM in China in 2021 was 4.1-fold of that in 1990, while the mortality and DALYs rates were 3.3-fold and 2.8-fold of those in 1990, respectively. From 1990 to 2021, the average annual percentage change of prevalence, mortality, and DALY rate of ACM were 4.96% (95% confidence interval (<i>CI</i>) 4.67%-5.25%), 3.94% (95%<i>CI</i> 3.63%-4.24%), and 3.65% (95%<i>CI</i> 3.36%-3.93%), respectively, showing an overall trend of initial increase followed by stabilization. Specifically, the annual percentage change peaked at 15.73% (95%<i>CI</i> 14.51%-16.96%) for prevalence during 2000-2004, 8.42% (95%<i>CI</i> 7.89%-8.96%) for mortality during 2004-2011, and 9.80% (95%<i>CI</i> 8.72%-10.89%) for DALYs during 2005-2009. The disease burden exhibited an inverted U-shaped distribution with age. The peaks of case number and prevalence emerged in the 45-54 years age group, whereas the peaks of death number and DALYs occurred in the 50-59 years age group. Across all age groups under 90 years, males bore a higher burden of ACM in terms of prevalence, mortality, and DALYs than females, with the overall prevalence, mortality, and DALY rate being 7.4-fold, 7.7-fold, and 12.1-fold those of females, respectively. Decomposition analysis revealed that epidemiological factors were the primary driver of changes in the burden of ACM in China (contribution ratio: 43.56%-67.17%), followed by population aging (19.98%-33.56%) and population growth (12.84%-22.88%). <b>","PeriodicalId":38755,"journal":{"name":"中华心血管病杂志","volume":"54 3","pages":"310-316"},"PeriodicalIF":0.0,"publicationDate":"2026-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147500105","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[A case of hereditary transthyretin amyloidosis cardiomyopathy complicated with monoclonal gammopathy of undetermined significance].","authors":"J Hua, Q B Dong, S Y Zhang, H Yan, Q Chen","doi":"10.3760/cma.j.cn112148-20250507-00335","DOIUrl":"10.3760/cma.j.cn112148-20250507-00335","url":null,"abstract":"","PeriodicalId":38755,"journal":{"name":"中华心血管病杂志","volume":"54 3","pages":"317-320"},"PeriodicalIF":0.0,"publicationDate":"2026-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147499995","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Application of transcatheter edge-to-edge repair in the treatment of papillary muscle rupture of mitral valve after acute myocardial infarction].","authors":"X Chen, Y W Lin, M L Su, X Chen, F Q Meng, H B Huang, Y E Yao, P P Yan, H M Wen, X J Wu, B Wang, Y Wang","doi":"10.3760/cma.j.cn112148-20250128-00076","DOIUrl":"10.3760/cma.j.cn112148-20250128-00076","url":null,"abstract":"<p><p><b>Objective:</b> To preliminarily investigate the clinical feasibility, early efficacy, and safety of transcatheter edge-to-edge repair (TEER) in patients with acute mitral regurgitation caused by papillary muscle rupture complicating acute myocardial infarction (AMI). <b>Methods:</b> The study is a retrospective case series. A retrospective analysis was conducted on clinical data of 12 patients with AMI complicated by papillary muscle rupture and severe mitral regurgitation who underwent TEER at Xiamen Cardiovascular Hospital affiliated to Xiamen University from December 2021 to October 2024. Collected data included demographic characteristics, diagnostics and treatment processes, in-hospital outcomes data. Procedural success of TEER was defined as successful grasping of the anterior and posterior mitral leaflets and reduction of mitral regurgitation to grade 2+or less. Patients were followed up for 30 days post-procedure to evaluate survival status and the severity of mitral regurgitation. <b>Results:</b> The mean age of the patients was 67.4 years, with 10 males. Eleven patients were diagnosed with ST-segment elevation myocardial infarction, and 11 out of 12 cases involved complete rupture of the posteromedial papillary muscle. Cardiogenic shock was present in 10 patients and the median Society of Thoracic Surgeons score was 51.9%. Procedural success was achieved in all 12 patients, with mitral regurgitation reduced to ≤2+immediately post-procedure. Eleven patients survived to discharge, and no device-or procedure-related complications occurred during the perioperative period. During the follow-up period, 2 patients died and 1 was readmitted for acute heart failure. At the 30-day follow-up, 9 patients maintained a mitral regurgitation grade of ≤2+. <b>Conclusions:</b> TEER is technically feasible for treating acute severe mitral regurgitation caused by papillary muscle rupture following AMI. It can effectively reduce mitral regurgitation and improve hemodynamic status in selected high-risk patients in the short term. However, these findings necessitate further validation through larger-scale multicenter studies and long-term follow-up.</p>","PeriodicalId":38755,"journal":{"name":"中华心血管病杂志","volume":"54 3","pages":"283-288"},"PeriodicalIF":0.0,"publicationDate":"2026-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147500006","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Role of lymphatic network in cardiac repair post myocardial infarction].","authors":"J Q He, D L Zhang, C H Yan, Y L Han","doi":"10.3760/cma.j.cn112148-20260121-00053","DOIUrl":"10.3760/cma.j.cn112148-20260121-00053","url":null,"abstract":"","PeriodicalId":38755,"journal":{"name":"中华心血管病杂志","volume":"54 3","pages":"328-332"},"PeriodicalIF":0.0,"publicationDate":"2026-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147500138","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[The mechanism of Rap1GAP in ventricular hypertrophy and interstitial fibrosis induced by angiotensin Ⅱ].","authors":"X Y Li, T T Shan, Y Yao, Y Q Zhang, Z Zhao","doi":"10.3760/cma.j.cn112148-20260115-00035","DOIUrl":"10.3760/cma.j.cn112148-20260115-00035","url":null,"abstract":"&lt;p&gt;&lt;p&gt;&lt;b&gt;Objective:&lt;/b&gt; To investigate the role of Rap1GAP in myocardial hypertrophy and fibrosis and its potential mechanism. &lt;b&gt;Methods:&lt;/b&gt; In animal experiments, 20 cardiac-specific Rap1GAP knockout mice (Rap1GAP&lt;sup&gt;Δ/Δ&lt;/sup&gt;) and 20 Rap1GAP homozygous floxed mice (Rap1GAP&lt;sup&gt;fl/fl&lt;/sup&gt;), aged 6-8 weeks, were divided into four groups: Rap1GAP&lt;sup&gt;fl/fl&lt;/sup&gt;+saline group, Rap1GAP&lt;sup&gt;Δ/Δ&lt;/sup&gt;+saline group, Rap1GAP&lt;sup&gt;fl/fl&lt;/sup&gt;+AngⅡ group, and Rap1GAP&lt;sup&gt;Δ/Δ&lt;/sup&gt;+AngⅡ group. Echocardiography was used to assess cardiac function in each group. HE staining was performed to observe the overall structure and cellular morphology of myocardial tissue. Wheat germ agglutinin staining was used to measure the cross-sectional area of cardiomyocytes. Masson staining and Sirius red staining were employed for quantitative analysis of myocardial fibrosis levels and collagen proportion. Western blot was used to detect the protein expression levels of Rap1GAP, α-smooth muscle actin (α-SMA), atrial natriuretic peptide (ANP), β-myosin heavy chain (β-MHC), collagen type Ⅰ, collagen type Ⅲ, transforming growth factor-β1 (TGF-β1), phosphorylated extracellular regulated kinase (p-ERK), extracellular regulated kinase (ERK), phosphorylated c-Jun N-terminal kinase (p-JNK), c-Jun N-terminal kinase (JNK), phosphorylated p38 mitogen-activated protein kinase (p-p38), p38 mitogen-activated protein kinase (p38), phosphorylated nuclear factor κB (p-NF-κB), and nuclear factor κB (NF-κB) in myocardial tissue. In cell experiments, primary cardiomyocytes and cardiac fibroblasts were isolated from 1-3-day-old Wistar rat neonates. Rap1GAP expression was knocked down by transfecting Rap1GAP small interfering RNA (si-Rap1GAP), and cells were divided into si-control (negative control siRNA)+saline group, si-Rap1GAP+saline group, si-control+AngⅡ group, and si-Rap1GAP+AngⅡ group. Rap1GAP was overexpressed by infecting with Rap1GAP adenovirus (Ad-Rap1GAP), and cells were divided into Ad-GFP (GFP empty vector adenovirus)+saline group, Ad-Rap1GAP+saline group, Ad-GFP+AngⅡ group, and Ad-Rap1GAP+AngⅡ group. For inhibitor rescue experiments, cardiac fibroblasts infected with Ad-Rap1GAP or Ad-GFP were treated with 10 μmol/L p38 inhibitor (SB203580) or TGF-β1 inhibitor (pirfenidone), forming Ad-Rap1GAP+AngⅡ+SB203580 group, Ad-Rap1GAP+Ang+pirfenidone group, Ad-GFP+AngⅡ+SB203580 group and Ad-GFP+Ang+pirfenidone group. Immunofluorescence staining was used to detect the expression levels of Rap1GAP, α-SMA, and proliferating cell nuclear antigen (PCNA) in cells. Dihydroethidium staining was employed to measure reactive oxygen species (ROS) levels. Western blot was used to detect the expression levels of target proteins (consistent with animal experiments). &lt;b&gt;Results:&lt;/b&gt; In animal experiments, compared with the Rap1GAP&lt;sup&gt;fl/fl&lt;/sup&gt;+AngⅡ group, the Rap1GAP&lt;sup&gt;Δ/Δ&lt;/sup&gt;+AngⅡ group showed larger left ventricular end-diastolic diameter and left ventricular end-systolic diameter, while the c","PeriodicalId":38755,"journal":{"name":"中华心血管病杂志","volume":"54 3","pages":"297-309"},"PeriodicalIF":0.0,"publicationDate":"2026-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147500093","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Moderate-intensity statin plus ezetimibe: time to rethink it as an optimal initial lipid-lowering strategy].","authors":"S Li, H H Liu, J J Li","doi":"10.3760/cma.j.cn112148-20251226-00913","DOIUrl":"10.3760/cma.j.cn112148-20251226-00913","url":null,"abstract":"","PeriodicalId":38755,"journal":{"name":"中华心血管病杂志","volume":"54 3","pages":"249-256"},"PeriodicalIF":0.0,"publicationDate":"2026-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147500083","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[The application of cardiopulmonary exercise test in heart failure with preserved ejection fraction].","authors":"M Y Liu, K Yang, W J Lu, P Xie","doi":"10.3760/cma.j.cn112148-20260120-00049","DOIUrl":"10.3760/cma.j.cn112148-20260120-00049","url":null,"abstract":"","PeriodicalId":38755,"journal":{"name":"中华心血管病杂志","volume":"54 3","pages":"343-348"},"PeriodicalIF":0.0,"publicationDate":"2026-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147500090","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[A case of left ventricular apical hypoplasia].","authors":"Y T Huang, L W Qiu, D Han, L Hua, Q Y Xi, X B Zhong, L Gao, H Zeng","doi":"10.3760/cma.j.cn112148-20260203-00075","DOIUrl":"10.3760/cma.j.cn112148-20260203-00075","url":null,"abstract":"","PeriodicalId":38755,"journal":{"name":"中华心血管病杂志","volume":"54 3","pages":"321-323"},"PeriodicalIF":0.0,"publicationDate":"2026-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147499971","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[The safety and efficacy of adeno-associated virus-mediated LDLR transfection in homozygous familial hypercholesterolemia].","authors":"G Gao, C B Xu, R F Li, T Zheng, J R Shao, X K Wang, P N Liu, G Wang, L X Jiang, G Qu, T Chen, J Q She, Y B Luo, Z Y Yuan, Y Wu","doi":"10.3760/cma.j.cn112148-20251115-00804","DOIUrl":"10.3760/cma.j.cn112148-20251115-00804","url":null,"abstract":"<p><p><b>Objective:</b> To evaluate the safety and efficacy of an adeno-associated virus vector carrying an optimized human low density lipoprotein receptor (LDLR) gene (NGGT006) in the treatment of homozygous familial hypercholesterolemia (HoFH) with LDLR mutations. <b>Methods:</b> This is an open-label, single-center, single-arm, non-randomized, investigator-initiated clinical trial. According to the dose-escalation principle, enrolled HoFH patients received a single injection of NGGT006 at three different doses: low dose (7.5×10¹² vg/kg), medium dose (1.5×10¹³ vg/kg), or high dose (3.0×10¹³ vg/kg). The primary endpoint of this study was the safety of NGGT006 treatment, evaluated by the incidence of drug-related adverse events and serious adverse events, and the efficacy of NGGT006 treatment, assessed by percentage and absolute changes in low density lipoprotein-cholesterol (LDL-C) levels. The early results of the first 3 patients after NGGT006 therapy in a 64-week follow-up were reported. <b>Results:</b> The 3 patients were aged 29 to 33 years, including 2 males, and the baseline serum LDL-C levels ranged from 8.95 to 11.17 mmol/L. No effective reduction in LDL-C levels was observed in patients 1 and 2, who were treated with low dose and medium dose of NGGT006, respectively. Patient 3 treated with a high dose of NGGT006 showed a rapid and persistent decrease in LDL-C levels. At the 64-week follow-up, the LDL-C level reduced from 11.17 mmol/L to 0.28 mmol/L, with a relative change of 97.49% compared with baseline. During the entire follow-up period, there were no serious adverse events in any of the patients. Only adverse events graded 2 or lower occurred, such as liver enzyme elevation and mild fever. <b>Conclusions:</b> NGGT006 gene therapy is generally safe and well-tolerated in HoFH patients with LDLR mutations. High-dose NGGT006 treatment can significantly reduce LDL-C levels. Further research is needed to evaluate its long-term efficacy.</p>","PeriodicalId":38755,"journal":{"name":"中华心血管病杂志","volume":"54 3","pages":"266-272"},"PeriodicalIF":0.0,"publicationDate":"2026-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147500134","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}